Preclinical Cro services in
Muscle (Sarcopenia)
Go beyond traditional endpoints with advanced muscle analyses. Our cutting-edge approach is shaping the future of muscle imaging endpoints in preclinical drug discovery. Gubra’s proprietary 3D imaging platform enables automated quantification of multiple histological endpoints in intact rodent hind limbs. Seamlessly integrating in vivo metabolic profiling, functional assessments, and targeted 2D histological analysis, our platform delivers robust, data-driven insights to accelerate sarcopenia and muscle-wasting drug development.
Why choose Gubra?
-
-
Expert scientific guidance in preclinical muscle research
-
Fully integrated metabolic, functional, and histological services
-
Unique 3D imaging platform for high-resolution morphometrics analyses in intact muscle groups
- Muscle imaging platform supporting both in-house studies and externally shipped samples
- Acute mouse models of muscle atrophy and cachexia
-
Consult with Marco Tozzi
Principal Scientist, Scientific Sales
Advance your drug development with our fully integrated muscle research platform.
Fully Integrated Skeletal Muscle Metabolic, Functional, and 3D Imaging Services
Our muscle research platform enables comprehensive efficacy assessment across muscle size, composition, and functional performance. Leveraging AI-powered 3D imaging, we deliver high-resolution, quantitative analysis of diverse histological endpoints within individual muscle compartments in the intact limb. Together with advanced in vivo and ex vivo readouts, this creates a high-content, multidimensional view of muscle biology.
Main Efficacy Study Offerings
Detailed
Body composition analysis
Comprehensive
Metabolic profiling
In-depth
Muscle tissue assessment
High-throughput
Quantitative 3D and 2D muscle imaging
Ex vivo
Muscle functional analysis
Complete
Mouse models of muscle athropy and cachexia
Investigate your compound’s mode of action
Advanced Muscle Profiling Platform
Quantitative 3D imaging
-
- High-throughput 3D light sheet fluorescence microscopy
- AI-powered muscle segmentation
- Quantification on whole-limb and individual intact muscles
- Muscle and bone volume
- Capillary and nerve density, fibrosis
- 3D-to-2D histology analysis
Muscle function assessment
- Grip strength test
- Ex vivo muscle contractile dynamics
- Ex vivo muscle force production
- Ex vivo muscle fatigue and recovery
- Automated and unbiased data quantification
Quantitative 2D histology
- Fibre counts and cross-sectional area (Laminin)
- Fibre type I and II analysis (MYH2-4-7)
- Myosteatosis (Oil Red O, hematoxylin-eosin)
- Glycogen storage (Periodic acid–Schiff)
- Glucose transport (GLUT4)
- Capillary density and fibre-to-capillary ratio (CD31+Laminin)
In vivo endpoints
-
- Body weight and food intake
-
Body composition analysis
- Locomotor activity monitoring
- Plasma biomarkers and biochemistry
- Energy expenditure assessment at thermoneutrality
- Terminal muscle weight
Additional Endpoints
-
- MicroCT for quantitative 3D assessment of bone architecture
- Target engagement, e.g. intramuscular dosing, assessment of drug molecular signaling signature, or direct drug application in our ex vivo muscle contraction assay
Accelerate your muscle-targeted drug development
Muscle Atrophy and Cachexia Mouse Models
Dexamethasone-induced muscle athrophy
- Body weight loss without affecting food intake
- Lean mass loss with limited, transient changes in fat mass
- Reduced skeletal muscle mass and volume across multiple compartments
- Reduced muscle contraction force
Cisplatin-induced cachexia
- Reduced food intake and robust body weight loss
- Progressive loss of lean and fat mass
- Reduced skeletal muscle mass cross multiple compartments
- Reduced visceral fat mass
PROGRESS YOUR STUDY WITH GREATER CERTAINTY
3D imaging of the entire hindlimb musculoskeletal system
Accurate assessment of muscle mass and morphology remains a key challenge in preclinical drug development for sarcopenia and cachexia. Gubra leverages industry-leading 3D imaging to resolve muscle architecture at single-cell resolution and quantify treatment responses across intact skeletal muscle compartments. This comprehensive, IND-enabling approach delivers precise visualization and robust quantifiable endpoints, providing deep insights into your preclinical candidate.
Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650